Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Jan;51(1):55–60. doi: 10.1038/bjc.1985.8

Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial.

N Padmanabhan, F R Balkwill, J G Bodmer, R D Rubens
PMCID: PMC1976812  PMID: 3917678

Abstract

Effectiveness of recombinant DNA (rDNA) human interferon alpha 2 (IFN alpha 2) in advanced breast cancer was evaluated in 14 patients who had received prior endocrine and/or cytotoxic therapy. After randomization, 7 patients received IFN alpha 2 two million IU m-2 day-1, s.c., 3 times a week (schedule 1) and 7 patients received 50 million IU m-2 day-1, i.v., for 5 consecutive days, every 3 weeks (schedule 2). Treatment duration was 4-21 weeks in schedule 1 and 6-24 weeks (2-8 courses) in schedule 2. Regressions were not achieved with either schedule. Treatment was associated with significant toxicity and was more severe in schedule 2. Dose limiting toxicities were leukopenia, elevation of liver enzymes, hyperglycemia and fatigue. Serum IFN activity was low or undetectable in patients on schedule 1 and high in patients on schedule 2. At 24 h, serum IFN activity was detectable in only 1/6 patients on schedule 1 as compared to 3/7 patients on schedule 2. IFN neutralizing factors were detected in the serum of only 1 patient prior to treatment but none were detected in any of the patients during or after discontinuation of treatment (4-24 weeks). IFN alpha 2 increased the expression of both HLA class 1 antigens and beta 2 microglobulin in peripheral blood lymphocytes in vivo. This effect was dose related.

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balkwill F. R., Moodie E. M. Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res. 1984 Mar;44(3):904–908. [PubMed] [Google Scholar]
  2. Edelstein M. B., Schellekens H., Laurent T., Gauci L. A phase I clinical tolerance study of rDNA alpha 2 human interferon in patients with non-reticuloendothelial system malignancies. Eur J Cancer Clin Oncol. 1983 Jul;19(7):891–894. doi: 10.1016/0277-5379(83)90053-6. [DOI] [PubMed] [Google Scholar]
  3. Gutterman J. U., Blumenschein G. R., Alexanian R., Yap H. Y., Buzdar A. U., Cabanillas F., Hortobagyi G. N., Hersh E. M., Rasmussen S. L., Harmon M. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep;93(3):399–406. doi: 10.7326/0003-4819-93-3-399. [DOI] [PubMed] [Google Scholar]
  4. Gutterman J. U., Fine S., Quesada J., Horning S. J., Levine J. F., Alexanian R., Bernhardt L., Kramer M., Spiegel H., Colburn W. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med. 1982 May;96(5):549–556. doi: 10.7326/0003-4819-96-5-549. [DOI] [PubMed] [Google Scholar]
  5. Hokland M., Heron I., Berg K. Increased expression of beta 2-microglobulin and histocompatibility antigens on human lymphoid cells induced by interferon. J Interferon Res. 1981;1(4):483–494. doi: 10.1089/jir.1981.1.483. [DOI] [PubMed] [Google Scholar]
  6. Horning S. J., Levine J. F., Miller R. A., Rosenberg S. A., Merigan T. C. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA. 1982 Mar 26;247(12):1718–1722. [PubMed] [Google Scholar]
  7. Nethersell A., Smedley H., Katrak M., Wheeler T., Sikora K. Recombinant interferon in advanced breast cancer. Br J Cancer. 1984 May;49(5):615–620. doi: 10.1038/bjc.1984.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Oldham R. R. Toxic effects of interferon. Science. 1983 Feb 25;219(4587):902–902. doi: 10.1126/science.6186027. [DOI] [PubMed] [Google Scholar]
  9. Rohatiner A. Z., Prior P. F., Burton A. C., Smith A. T., Balkwill F. R., Lister T. A. Central nervous system toxicity of interferon. Br J Cancer. 1983 Mar;47(3):419–422. doi: 10.1038/bjc.1983.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sangster G., Kaye S. B., Calman K. C., Toy J. L. Cutaneous vasculitis associated with interferon. Eur J Cancer Clin Oncol. 1983 Nov;19(11):1647–1649. doi: 10.1016/0277-5379(83)90099-8. [DOI] [PubMed] [Google Scholar]
  11. Sherwin S. A., Knost J. A., Fein S., Abrams P. G., Foon K. A., Ochs J. J., Schoenberger C., Maluish A. E., Oldham R. K. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA. 1982 Nov 19;248(19):2461–2466. [PubMed] [Google Scholar]
  12. Sherwin S. A., Mayer D., Ochs J. J., Abrams P. G., Knost J. A., Foon K. A., Fein S., Oldham R. K. Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial. Ann Intern Med. 1983 May;98(5 Pt 1):598–602. doi: 10.7326/0003-4819-98-5-598. [DOI] [PubMed] [Google Scholar]
  13. Trunkey D. D. Trauma. Accidental and intentional injuries account for more years of life lost in the U.S. than cancer and heart disease. Among the prescribed remedies are improved preventive efforts, speedier surgery and further research. Sci Am. 1983 Aug;249(2):28–35. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES